30 October 2025 in JAC-Antimicrobial Resistance
Objectives: To evaluate the synergistic activity of ampicillin/sulbactam plus ceftazidime/avibactam in a collection of carbapenem-resistant Acinetobacter baumannii (CR-Ab) from different regions in Peru. Materials and methods: One hundred and eighty-four CR-Ab isolates were included in this study. They were identified by amplification of blaOXA-51 and confirmed by MALDI-TOF (matrix-assisted laser desorption ionization time of flight) mass spectrometry and 16S rRNA sequencing. Susceptibility to ampicillin/sulbactam and carbapenems was determined by the disc diffusion method. Synergy was assessed using discs containing ampicillin/sulbactam and ceftazidime/avibactam. The EDTA-disc synergy test was used to screen metallo-β-lactamase-producing isolates, and in isolates showing synergy, the presence of blaNDM was confirmed by PCR. Statistical analysis was performed using Fisher’s exact test. Results: High levels of resistance to ampicillin/sulbactam were found in the study. Thus, 1.1% (2/184), 11.4% (21/184) and 87.5% (161/184) of isolates were classified as susceptible, intermediate and resistant to ampicillin/sulbactam, respectively. Synergistic activity was observed in 97.2% of the non-susceptible CR-Ab isolates. The presence of metallo-β-lactamase producers (all blaNDM) was observed in three isolates (1.6%). Conclusions: These findings demonstrate high levels of synergistic activity between ampicillin/sulbactam and ceftazidime/avibactam and their potential use as a treatment for CR-Ab.
1 January 2025 in Journal of Tropical Medicine
Background: Common identification techniques do not differentiate among members of the Acinetobacter calcoaceticus–baumannii (ACB) complex, and the presence of non‐ baumannii Acinetobacter is often misinterpreted. The b l a OXA−51 gene is located within the chromosome of Acinetobacter baumannii . Despite its plasmid dissemination to other members of the genus, it may be considered in initial species screening. Thus, this study aimed to determine the presence of b l a OXA−51 ‐negative Acinetobacter spp. as a cause of infection in Peru. Methods: Two hundred ninety‐eight ACB complex isolates from different regions of Peru were isolated between January 2018 and March 2024. Of these, 272 and 25 were confirmed as hospital‐acquired and community infections, respectively. The presence of b l a OXA−51 was determined by polymerase chain reaction, and the susceptibility levels to 12 antimicrobial agents were determined. Results: The results showed that 38 (12.7%) isolates were b l a OXA−51 ‐negative. These isolates were frequent among community infections (13/25, p < 0.0001), often causing urine infections. They showed significantly lower levels of resistance to almost all antimicrobial agents tested, and most of them were recovered from regions outside metropolitan Lima. Conclusion: A relevant number of infections by non‐ baumannii Acinetobacter species in Peru is suggested, highlighting the need for systematic identification of these species in the country.